New data on DLBCL in the UK and its impact on treatment decisions
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2022-04-26
Просмотров: 249
Описание: In this video, Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, gives an overview on new data in diffuse large B-cell lymphoma (DLBCL) and how this may influence current and future treatment decisions. Dr Osborne first discusses factors that are currently changing treatment practice, drawing focus on the benefits of using bone prophylaxis and CNS prophylaxis in high-risk patients. Following this, Dr Osborne discusses the exciting results from the POLARIX study (NCT03274492), investigating the use of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with previously untreated DLBCL. Finally, Dr Osborne discusses how identifying high-risk patients upfront and using novel agents including chimeric antigen receptor T-cell (CAR-T) therapy in the frontline setting may improve patient outcome, as seen in the ZUMA-12 study (NCT03761056). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
